Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 6/2019

01-11-2019 | Breast Cancer | Original Article

Transgelin-2 expression in breast cancer and its relationships with clinicopathological features and patient outcome

Authors: Ruifang Hao, Yang Liu, Qian Du, Leichao Liu, Siying Chen, Haisheng You, Yalin Dong

Published in: Breast Cancer | Issue 6/2019

Login to get access

Abstract

Background

Transgelin-2 is an actin-binding protein that is widely expressed in various tissues and organs of the body, and reportedly may participate in the development and progression of multiple cancers. However, the clinical significance of transgelin-2 still remains controversial. We, therefore, aimed to determine the expression of transgelin-2 in breast cancer as well as its correlation with the tumorigenesis, progression and prognosis of human breast cancer.

Methods

We collected tissues of 58 breast cancer patients from our hospital and 1090 samples from The Cancer Genome Atlas (TCGA) database. X-tile software was used to divide the transgelin-2 mRNA expression level in the database, logistic regression model was used to identify independent factors influencing transgelin-2 mRNA expression, and then Cox regression and Kaplan–Meier analysis were used to find factors that influence survival of breast cancer.

Results

Transgelin-2 was significantly overexpressed in breast cancer tissues from our hospital and receiver operating characteristic (ROC) curve indicated that transgelin-2 may have diagnostic value. Meanwhile, estrogen receptor (ER) was in inverse correlation with transgelin-2 protein and mRNA expression, and transgelin-2 expression was positively correlated with Ki67 in breast cancer tissues. Logistic regression model revealed that TNM stage, ER and progesterone receptor (PR) status were independent factors for transgelin-2 mRNA expression. Patients with high transgelin-2 mRNA expression showed a poor survival and the trend was statistically significant only in ER-negative patients.

Conclusions

Transgelin-2 was expressed significantly higher in breast cancer cells and correlated with some clinicopathological factors. High transgelin-2 expression might predict poor prognosis for ER-negative patients.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef
2.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRef
3.
Lin B, Zhang L, Li D, Sun H. MED23 in endocrinotherapy for breast cancer. Oncol Lett. 2017;13(6):4679–84.CrossRef
4.
Salatino M, Girotti MR, Rabinovich GA. Glycans pave the way for immunotherapy in triple-negative breast cancer. Cancer Cell. 2018;33(2):155–7.CrossRef
5.
Reinert T, Goncalves R, Ellis MJ. Current status of neoadjuvant endocrine therapy in early stage breast cancer. Curr Treat Options Oncol. 2018;19(5):23.CrossRef
6.
Bai F, Yin Y, Chen T, Chen J, Ge M, Lu Y, et al. Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer. Int J Nanomed. 2018;13:1327–39.CrossRef
7.
Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 2010;46(3):308–16.CrossRef
8.
Na BR, Kim HR, Piragyte I, Oh HM, Kwon MS, Akber U, et al. TAGLN2 regulates T cell activation by stabilizing the actin cytoskeleton at the immunological synapse. J Cell Biol. 2015;209(1):143–62.CrossRef
9.
Koudelkova P, Costina V, Weber G, Dooley S, Findeisen P, Winter P, et al. Transforming growth factor-beta drives the transendothelial migration of hepatocellular carcinoma cells. Int J Mol Sci. 2017;18(10):2119.CrossRef
10.
Elsner M, Rauser S, Maier S, Schone C, Balluff B, Meding S, et al. MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett’s adenocarcinoma. J Proteom. 2012;75(15):4693–704.CrossRef
11.
Zhang Y, Ye Y, Shen D, Jiang K, Zhang H, Sun W, et al. Identification of transgelin-2 as a biomarker of colorectal cancer by laser capture microdissection and quantitative proteome analysis. Cancer Sci. 2010;101(2):523–9.CrossRef
12.
Chen CL, Chung T, Wu CC, Ng KF, Yu JS, Tsai CH, et al. Comparative tissue proteomics of microdissected specimens reveals novel candidate biomarkers of bladder cancer. Mol Cell Proteom. 2015;14(9):2466–78.CrossRef
13.
Yakabe K, Murakami A, Kajimura T, Nishimoto Y, Sueoka K, Sato S, et al. Functional significance of transgelin-2 in uterine cervical squamous cell carcinoma. J Obstet Gynaecol Res. 2016;42(5):566–72.CrossRef
14.
Hill JJ, Tremblay TL, Pen A, Li J, Robotham AC, Lenferink AE, et al. Identification of vascular breast tumor markers by laser capture microdissection and label-free LC–MS. J Proteom Res. 2011;10(5):2479–93.CrossRef
15.
Yoshida A, Okamoto N, Tozawa-Ono A, Koizumi H, Kiguchi K, Ishizuka B, et al. Proteomic analysis of differential protein expression by brain metastases of gynecological malignancies. Hum Cell. 2013;26(2):56–66.CrossRef
16.
Chen S, Dong Q, Hu S, Cai J, Zhang W, Sun J, et al. Proteomic analysis of the proteins that are associated with the resistance to paclitaxel in human breast cancer cells. Mol BioSyst. 2014;10(2):294–303.CrossRef
17.
Zheng X, Chen S, Yang Q, Cai J, Zhang W, You H, et al. Salvianolic acid a reverses the paclitaxel resistance and inhibits the migration and invasion abilities of human breast cancer cells by inactivating transgelin 2. Cancer Biol Ther. 2015;16(9):1407–14.CrossRef
18.
Cai J, Chen S, Zhang W, Zheng X, Hu S, Pang C, et al. Salvianolic acid A reverses paclitaxel resistance in human breast cancer MCF-7 cells via targeting the expression of transgelin 2 and attenuating PI3 K/Akt pathway. Phytomedicine. 2014;21(12):1725–32.CrossRef
19.
Cai J, Chen S, Zhang W, Hu S, Lu J, Xing J, et al. Paeonol reverses paclitaxel resistance in human breast cancer cells by regulating the expression of transgelin 2. Phytomedicine. 2014;21(7):984–91.CrossRef
20.
Xu SG, Yan PJ, Shao ZM. Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis. J Cancer Res Clin Oncol. 2010;136(10):1545–56.CrossRef
21.
Ma J, Kong Y, Nan H, Qu S, Fu X, Jiang L, et al. Pleiotrophin as a potential biomarker in breast cancer patients. Clin Chim Acta. 2017;466:6–12.CrossRef
22.
Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology. 2017;49(2):166–71.CrossRef
23.
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174–83.CrossRef
Metadata
Title
Transgelin-2 expression in breast cancer and its relationships with clinicopathological features and patient outcome
Authors
Ruifang Hao
Yang Liu
Qian Du
Leichao Liu
Siying Chen
Haisheng You
Yalin Dong
Publication date
01-11-2019
Publisher
Springer Japan
Published in
Breast Cancer / Issue 6/2019
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-019-00981-4

Other articles of this Issue 6/2019

Breast Cancer 6/2019 Go to the issue

Original Article

Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers

Case Report

Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers

Original Article

Fatal events during clinical trials: an evaluation of deaths during breast cancer studies

Original Article

Simultaneous comparison between strain and shear wave elastography of breast masses for the differentiation of benign and malignant lesions by qualitative and quantitative assessments

Original Article

Tumor microenvironmental growth factors induce long-term estrogen deprivation resistance in breast cancer

Original Article

RETRACTED ARTICLE: Association of insulin-like growth factor 1 receptor and estrogen receptor with pathological complete response to neoadjuvant chemotherapy in HER2-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits